Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Implants / Devices
    • Merck launches cutting...

    Merck launches cutting edge fertility technologies in India

    Farhat NasimWritten by Farhat Nasim Published On 2019-02-28T09:05:56+05:30  |  Updated On 16 Aug 2021 12:00 PM IST


    The introduction of cutting-edge fertility technology complements Merck portfolio and promises to decrease manual labour, increases precision and thus optimizes IVF outcomes for patients in India.


    Mumbai: Improved assisted reproductive technology (ART) through higher precision, Merck offers a combined portfolio of drugs and technologies. Merck, a leading science and technology company, launched its cutting-edge fertility technology in India today. The business launched two devices, namely Geri® and Gavi®, as well as Gems®, a complete culture medium suite. This will be made available in partnership with GeneaBiomedx, to IVF clinics and hospitals.

    This new technology provides an environment that helps to reduce external stresses on the embryos of patients undergoing fertility treatment. Individually-controlled chambers allow the embryos of each patient to grow separately and real-time cameras attached to each chamber reduces the frequency of opening and closing the chambers in Geri®. Not only does this allow observation of the progress of embryo growth without removing the embryo from the chamber it also reduces the impact on the embryo of factors such as changes in gas concentration and temperature."Merck has a market-leading portfolio of drugs and offers an array of clinic optimization services. Fertility lab procedures involve various steps and variables which can impact the overall success rate of IVF treatment. The introduction of cutting-edge fertility technology complements our portfolio and promises to decrease manual labour, increases precision and thus optimizes IVF outcomes for patients in India. Studies say nearly 27.5 million* Indian couples are actively seeking solution for infertility and with this technology are in position to offer them better access to world-class treatment," said AnandramNarasimhan, General Manager -India Cluster, Merck Biopharma.

    Through the expansion of its portfolio of innovative pharmaceutical and technology products that fulfil unmet medical needs in the field of fertility treatment, Merck is aiming to provide broader range of products to help support Healthcare professionals to optimize treatment outcomes and fulfil the dream of becoming a parent. With this latest addition to its market-leading IVF drugs and services, Merck offers a comprehensive and holistic portfolio that facilitates IVF outcomes delivered by clinicians and specialists in India. About Gavi®, Geri® and Gems® Gavi® is the world's first automated vitrification instrument, developed with the aim to achieve a consistent and standardized vitrification process.

    Geri® is a benchtop incubator with individually controlled incubation chambers per patient to minimize disruptive events to the early-stage embryo. It also incorporates a time-lapse camera to capture images of embryos as they develop. Gems® is the latest generation of GeneaBiomedx's culture media suite for high-quality embryo cultivation. Gavi®, Geri® and Gems® are created by GeneaBiomedx, a company that creates and manufactures practical, accessible and precise fertility technologies that help standardize and automate fertility treatment. About Merck's Fertility Treatment Portfolio Merck offers a full portfolio of fertility drugs, including recombinant versions of the three natural hormones needed to treat infertility:

    Recombinant human follicle-stimulating hormone (r-hFSH)

    Recombinant human luteinising hormone (r-hLH)

    Recombinant human chorionic gonadotropin (r-hCG) Our portfolio of fertility treatments provides a solution for critical stages of the fertility treatment cycle and includes complementary products which can be used in conjunction with the recombinant gonadotropins during and after a fertility treatment cycle. References: * Call for Action: Expanding IVF Treatment in India (E&Y Report July 2015) All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service. About Merck Merck, a vibrant science and technology company operates across healthcare, life science and performance materials.

    Around 51,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices - Merck is everywhere.

    In 2017, Merck generated sales of 15.3 billion in 66 countries. Scientific exploration and responsible entrepreneurship have been key to Merck's technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials.


    Also Read: Merck to buy drug developer Immune Design for $300 million


    Assisted Reproductive Technologycutting edgefertility treatmentGAVIGEMsgerihealth careHealthcarehospitalsHuman Chorionic GonadotropinIndiaIVF clinicslatest medical devicemedical deviceMerckMerck Groupmerck launch
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok